1173 related articles for article (PubMed ID: 20129072)
1. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
2. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
Tiews S; Steinberg W; Schneider W; Hanrath C
J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
[TBL] [Abstract][Full Text] [Related]
3. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. HPV testing with cytology triage for cervical cancer screening in routine practice.
Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
[TBL] [Abstract][Full Text] [Related]
6. Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.
Horn J; Denecke A; Luyten A; Rothe B; Reinecke-Lüthge A; Mikolajczyk R; Petry KU
Br J Cancer; 2019 May; 120(10):1015-1022. PubMed ID: 30988395
[TBL] [Abstract][Full Text] [Related]
7. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
8. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
9. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
10. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
[TBL] [Abstract][Full Text] [Related]
13. Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.
Leinonen MK; Anttila A; Malila N; Dillner J; Forslund O; Nieminen P
Br J Cancer; 2013 Nov; 109(11):2941-50. PubMed ID: 24136148
[TBL] [Abstract][Full Text] [Related]
14. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
[TBL] [Abstract][Full Text] [Related]
15. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
17. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
18. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
20. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
